我自研六价轮状病毒疫苗完成首剂接种

Group 1 - The first six-valent rotavirus vaccine in China, covering six serotypes, completed its first dose administration in Wuhan on December 26 [1] - Rotavirus is a significant pathogen causing acute gastroenteritis in infants and young children, posing a continuous health challenge for children under five in China [1] - The World Health Organization identifies vaccination as the most economical and effective public health intervention to reduce the burden of rotavirus-related diseases, recommending it as a key vaccine for national immunization programs [1] Group 2 - The newly developed vaccine by China National Pharmaceutical Group's Wuhan Institute of Biological Products addresses both traditional and emerging rotavirus serotypes, reflecting recent monitoring trends [1] - Approved for market on September 12, the vaccine is classified as a Category 1 new drug for preventive biological products in China and is administered orally to infants aged 6 weeks to 36 weeks [1] - The nationwide vaccination campaign will be gradually initiated, with efforts to enhance vaccination service management, monitoring, and public health education [1][2]